Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia | Aplastic Anemia & MDS International Foundation

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Original Publication Date: 
Tuesday, October 9, 2018
Article Source: 
External Web Content

MDS/MPN (myelodysplastic syndromes/myeloproliferative neoplasms) is a disease of the blood and bone marrow with features of both MDS and MPN.  The most common form is CMML, or chronic myelomonocitic leukemia.  In CMML, abnormal blood cells (myeloblasts and myelocytes) accumulate in the bone marrow and other organs, and they interfere with the production of healthy blood cells.  This study led by Dr. Eric Padron through the MDS Clinical Research Consortium sites showed promising results for a new CMML treatment.  

This Phase I/II study was conducted by Dr. Eric Padron of the H. Lee Moffitt Cancer Center between April 2015 and October 2016. It  was done to test the efficiency of ruxolitinib, known as a JAK1/2 inhibitor, for treating CMMLAccording to Dr. Padron and colleagues,  the outcome of the Phase II study is  encouraging. In results published in the journal Blood they concluded, “ruxolitinib has promising activity in CMML patients with particular benefit in those with proliferative symptoms and may have disease-modifying activity.” Further clinical study is needed to validate the biomarkers of response and effectiveness of  ruxolitinib in CMML.

For more information, please visit: http://www.bloodjournal.org/content/130/Suppl_1/162?sso-checked=true